463976-07-0

Basic information

• Product Name: 6-(5-Chloro-3-methyl-1-benzofuran-2-ylsulfonyl)pyridazin-3(2H)-one
• CAS NO: 463976-07-0
• Molecular Formula: C₁₃H₉ClN₂O₄S
• Molecular Weight: 324.74468
• Mol File: 463976-07-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-(5-Chloro-3-methyl-1-benzofuran-2-ylsulfonyl)pyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(5-Chloro-3-methyl-1-benzofuran-2-ylsulfonyl)pyridazin-3(2H)-one(463976-07-0)
• EPA Substance Registry System: 6-(5-Chloro-3-methyl-1-benzofuran-2-ylsulfonyl)pyridazin-3(2H)-one(463976-07-0)

Safety Data

• Hazardous Substances Data: 463976-07-0(Hazardous Substances Data)

Upstream product

• 463976-90-1 6-(5-chloro-3-methylbenzofuran-2-sulfenyl)-3-methoxypyridazine 
• 463976-08-1 5-chloro-2-mercapto-3-methylbenzofuran 
• 463976-10-5 6-(5-chloro-3-methylbenzofuran-2-sulfenyl)-2H-pyridazin-3-one 
• 463976-11-6 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-3-methoxypyridazine 
• 463976-10-5 6-(5-chloro-3-methyl-benzofuran-2-ylsulfanyl)-pyridazin-3-ol 
• 1125-41-3 5-chloro-3-methylbenzofuran 

Downstream Products

• 1125-41-3 5-chloro-3-methylbenzofuran 

Relevant articles and documents

SPRAY DRIED FORMULATION

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/mL in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt% of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt% of the solid dispersion.

Process and intermediates for pyridazinone antidiabetic agents

The present invention relates to a process for preparing pyridazinone aldose reductase inhibitors which are useful in the prevention and/or treatment of diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. The invention also relates to novel intermediates useful in preparing those aldose reductase inihibitors.

Pyridazinone aldose reductase inhibitors

The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adendsine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents.